Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dyadic International Inc., DE

Novavax

Pfizer

The process of lining up the next wave of vaccines – Vax 2.0 – is likely already underway behind closed doors at major science institutes, throughout top research think-tanks, and at the home bases of the major vaccine-oriented pharma players. Vax 2.0 is no longer a theory.

Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA)

This potential market is definitely large enough to motivate drugmakers to go after it.

How Big Is the COVID Vaccine Market for Younger Kids?

Are Pfizer and Moderna Trying to Boost Sales With an Early COVID Booster Shot?

Moderna Inc (NASDAQ: MRNA) expects to launch a single-dose COVID-19 vaccine in India in 2022 and is in talks with Cipla, among other Indian firms, reports Economic Times. While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021.

Moderna Sees Single-Dose COVID-19 Vaccine Launch In India In 2022

The company should submit its request for the FDA to authorize the use of its vaccine in those 12 and older in a couple of weeks.

Moderna's Teen COVID-19 Vaccine Trial Hits High Marks

Moderna Inc (NASDAQ:MRNA) is the second company -- after Pfizer (PFE) -- to develop a Covid-19 vaccine proven to be highly effective in younger age groups.

MRNA Climbs on Upbeat Vaccine Update for Younger Age Groups

Moderna says its COVID-19 vaccine is effective in teenagers

Shares of COVID-19 vaccine maker Moderna Inc (NASDAQ: MRNA) were trading higher by more than 2% Tuesday morning after announcing encouraging results from its TeenCOVE study. Study results Moderna said in a press release its Phase ⅔ study of its COVID-19 vaccine (mRNA-1273) in adolescents met its primary immunogenicity endpoint.

Moderna says COVID-19 vaccine ‘highly effective' in preventing illness in teens

Moderna Inc (NASDAQ: MRNA) has announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in adolescents has met the primary endpoint of non-inferior immunogenicity versus the Phase 3 study adult comparator group. In the study, no cases of COVID-19 were observed in participants who had received two doses of the vaccine.

Moderna's COVID-19 Vaccine Effective at Preventing Infection in Adolescents

Moderna sees positive results in Phase 2/3 vaccine trial among adolescents

Moderna's Covid-19 vaccine is the second shot behind Pfizer's to demonstrate high efficacy in younger age groups.

Moderna says its Covid vaccine is 100% effective in teens, plans to seek FDA OK in early June

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces TeenCOVE study of its COVID-19 vaccine in adolescents meets primary endpoint and plans to submit data to regulators in early June.

Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June

The biotech firm said it plans to submit data to regulators in early June.

Moderna Will Seek Authorization For Teen Covid Vaccine After Trial Shows 100% Efficacy

Moderna's coronavirus vaccine appears to be highly protective in 12-to-17-year-olds, the Massachusetts biotech said Tuesday in a press release, paving the way for the shot to be given widely to adolescents as soon as next month. If regulators give the green light, Moderna's vaccine would be the second COVID-19 shot to be authorized for people as young as 12, after the Pfizer-BioNTech vaccine . Both vaccine developers are studying their shots in even younger populations.

Moderna says its coronavirus vaccine is effective in teens, and the biotech plans to apply in early June for an expanded OK

The U.S. now supports waiving patent rights at the World Trade Organization for COVID-19 vaccines. How bad is this news?

Will the COVID Vaccine Companies Fall off the Patent Cliff?

CureVac B.V

With COVID-19 vaccines still scarce around the world, companies are announcing plans to expand production so as to speed up vaccine distribution worldwide. CuraVac N.V.

Two COVID-19 vaccine makers in the news: CureVac and Moderna expanding production

Moderna Inc (NASDAQ: MRNA) has inked a deal with South Korean CDMO Samsung Biologics for fill-finish duties for mRNA-1273, Moderna's COVID-19 vaccine. The company announced Friday that its vaccine was approved by the Japanese and South Korean governments.

Moderna, Samsung Biologics Ink Fill-Finish Pact For COVID-19 Shots In South Korea

CAMBRIDGE, Mass. & FARGO, N.D.--(BUSINESS WIRE)--Moderna and Aldevron announce expanded partnership for mRNA vaccine and therapeutic pipeline.

Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline

Shares in South Korean drug contract manufacturer Samsung BioLogics rose as much as 5.2% in early Monday trade, after it agreed to fill-finish manufacture Moderna's COVID-19 vaccine.

Samsung BioLogics shares rise after agrees to make Moderna COVID-19 vaccine

CAMBRIDGE, Mass. and INCHEON, South Korea, May 22, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, today announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine.

Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna and South Korea explore collaboration on mRNA vaccines.

Moderna and South Korea Explore Collaboration on mRNA Vaccines

Shares of Moderna were down 2.0% in trading on Friday after the company said its COVID-19 vaccine was authorized in South Korea for use in adults. South Korea has already purchased 40 million doses of the two-dose, mRNA vaccine.

Moderna's COVID-19 vaccine is authorized in South Korea

Japanese and South Korean regulators officially approved Moderna Inc's (NASDAQ:MRNA) Covid-19 vaccine, alongside the vaccine produced by AstraZeneca (AZN) and Oxford University.

Moderna Vaccine Gains Approval in Japan, South Korea

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ministry of Food and Drug Safety of South Korea (MFDS) authorizes Moderna's COVID-19 vaccine.

News for Moderna Stock (MRNA)